Motivation
Expert analysis of the Pfizer studies “Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine”, published in the NEJM. Serious flaws identified in trial design, conduct, data collection and reporting. Unblinding and crossover after 2 months. In the treatment group more participants became ill, and more participants died, than in the placebo group – Late inclusion of Children and Adolescents – etc etc.
Author
CCCA. Deanna McLeod.
Submitted By
Dr Herman Edeling
Supported By
Dr Stephen Schmidt
Type of Article
Independent Analysis